Trial site
Palmetto Retina Center
West Columbia, South Carolina 29169, United StatesNot linked to an institution yet
- 10running trials
- 11closed trials
The trials here
What the 21 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 25 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed10 trials
- Active, not recruiting6 trials
- Recruiting4 trials
- Terminated1 trial
- Lead sponsor
- Hoffmann-La Roche4 trials
- 4D Molecular Therapeutics2 trials
- Astellas Pharma Global Development, Inc.2 trials
- Greater Houston Retina Research2 trials
- Ocular Therapeutix, Inc.2 trials
- and 8 more
Running trials
Recruiting
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132· Phase 3· Ocular Therapeutix, Inc.· Source
Contact: Nitin Nigam, MD
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567· Phase 2/3· EyeBiotech Ltd.· Source
Contact: Study Coordinator
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Contact: Study Coordinator
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Active, not recruiting
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· Phase 3· 4D Molecular Therapeutics· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368· Phase 3· Kodiak Sciences Inc· Source
Active, not recruiting
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958· Phase 3· Ocular Therapeutix, Inc.· Source
Active, not recruiting
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT04108156· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
NCT06172257· Phase 3· Oculis· Source
Completed
Safety and Efficacy of Faricimab in Patients With NPDR
NCT05681884· Phase 2· Greater Houston Retina Research· Source
Completed
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041· Phase 2· Aviceda Therapeutics, Inc.· Source
Completed
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
NCT05642312· Phase 3· Hoffmann-La Roche· Source
Completed
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
NCT05536297· Phase 3· Astellas Pharma Global Development, Inc.· Source
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922· Phase 1/2· Genentech, Inc.· Source
Completed
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
NCT04708145· Phase 4· Greater Houston Retina Research· Source
Completed
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· Phase 3· Hoffmann-La Roche· Source
Terminated
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
NCT04566445· Phase 2· Gyroscope Therapeutics Limited· Source
Completed
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
NCT04503551· Phase 3· Hoffmann-La Roche· Source
Completed
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
NCT03364153· Phase 2· Astellas Pharma Global Development, Inc.· Source
Report an error